非酒精性脂肪性肝炎治疗的突破与尚存挑战
非酒精性脂肪性肝炎(NASH)已成为慢性肝病的主要原因,目前尚无获批疗法,但关键突破为未来治疗成功铺平道路。监管机构已接受关键替代终点,非侵入性检测使早期试验快速开展,多种有前景的化合物已进入后期开发。进一步改进组织学终点评估和开发非侵入性预测生物标志物的研究正在进行中。
要点
- NASH是慢性肝病的主要原因,目前尚无获批疗法。
- 监管机构已接受治疗试验的关键替代终点,为药物注册开辟路径。
- 非侵入性检测使早期试验快速开展,多种有前景化合物已进入后期开发。
核心结论
- NASH领域的重大突破为未来治疗成功铺平了道路。
- 进一步改进组织学终点评估和开发非侵入性预测生物标志物的研究正在进行中。
- 这将有助于改进成功试验的设计和可行性,最终为患者提供能改变疾病进程的治疗选择。
主要发现
- NASH已成为慢性肝病的主要原因。
- 对NASH发病机制理解的进展已确定了许多药理学靶点。
- 监管机构现已接受治疗试验的关键替代终点。
- 一套非侵入性检测使早期试验得以快速开展,从而提供治疗候选药物生物学和可能临床作用的早期迹象。
- 这产生了一些高度有前景化合物的疗效结果,这些化合物目前处于后期开发阶段。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Initially a condition that received limited recognition and whose clinical impact was controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic liver disease. Although there are no approved therapies, major breakthroughs, which will be reviewed here, have paved the way for future therapeutic successes. The unmet medical need in NASH is no longer disputed, and progress in the understanding of its pathogenesis has resulted in the identification of many pharmacological targets. Key surrogate outcomes for therapeutic trials are now accepted by regulatory agencies, thus creating a path for drug registration. A set of non-invasive measurements enabled early-stage trials to be conducted expeditiously, thus providing early indications on the biological and possibly clinical actions of therapeutic candidates. This generated efficacy results for a number of highly promising compounds that are now in late-stage development. Intense research aimed at further improving the assessment of histological endpoints and in developing non-invasive predictive biomarkers is underway. This will help improve the design and feasibility of successful trials, ultimately providing patients with therapeutic options that can change the course of the disease.
引用
- Ratziu V, Francque S, Sanyal A, et al. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 2022. PMID: 35589249. doi:10.1016/j.jhep.2022.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。